Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several concerns: a decline in net revenue, high operating expenses, and challenges in regulatory and reimbursement approvals. The Q&A reveals delays in guideline inclusion and vague responses on sales force expansion. Despite plans for European market entry, the financial strain and uncertainties overshadow potential growth. The stock price is likely to experience a negative reaction in the short term due to these factors.
Key Financial Performance
Net Revenue $17,000 for Q2 2025 compared to $24,000 for Q2 2024, a decrease due to lower sales activity.
Total Operating Expenses $9.3 million for Q2 2025, flat compared to the same period in 2024.
Research and Development Expenses $3.3 million for Q2 2025, down 24% from $4.4 million in Q2 2024 due to lower clinical study costs following the completion of the PRIME study and a shift toward commercialization.
Selling, General and Administrative Expenses $6.0 million for Q2 2025, up from $4.9 million in Q2 2024, reflecting investments in targeted commercial activities, market awareness, and strategic headcount additions.
Net Loss $8.0 million for Q2 2025, down from $8.3 million in Q2 2024, attributed to a focus on managing capital resources ahead of expected revenue expansion.
Cash, Cash Equivalents, and Available-for-Sale Securities $108.5 million as of June 30, 2025, expected to fund the company through significant adoption and commercial milestones through 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PreTRM Test: The company is advancing the commercialization of the PreTRM Test, focusing on generating data to demonstrate its efficacy and health economic benefits. The PRIME study results showed cost savings of $1,600 per member tested and potential savings of $4,000 to $20,000 per NICU day.
European Market Expansion: Sera is preparing to commercialize the PreTRM Test in Europe, focusing on the U.K., France, and Germany. The company plans to transition the test to an immunoassay and aims for regulatory submission in early 2026, with implementation starting mid-2026.
Medicaid Pilot Programs: The company is seeing traction in two states with high premature birth rates and growing momentum in two additional states. They aim to sign 2-4 pilot programs in the coming months.
Strategic Leadership Hires: Key hires include Lee Anderson as Chief Commercial Officer, Chuck Hyde as Head of Market Access, and Jennifer Zibuda as Head of Investor Relations to strengthen commercial reach and awareness.
Sales Force Expansion: The company is hiring additional sales representatives in targeted geographies to drive adoption of the PreTRM Test.
Data Publication and Awareness: Sera is focusing on publishing PRIME study results and additional data to influence guidelines and increase awareness among clinicians and payers.
Focus on Health Economic Benefits: The company is emphasizing the cost-saving benefits of the PreTRM Test to Medicaid and other payers to drive adoption.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Awareness and Data Generation: The company is heavily reliant on the publication of its PRIME study results to drive market awareness and stakeholder engagement. Delays in publication or lack of compelling data could hinder reimbursement strategies and market adoption.
Medicaid and Payer Engagement: While there is traction in Medicaid pilot programs, the process is still early, and there is uncertainty in signing agreements with Medicaid programs and other payers. Failure to secure these agreements could impact revenue growth.
Sales and Marketing Expansion: The company is investing in hiring additional sales representatives and building a commercial team, but it may take several quarters for these efforts to translate into meaningful adoption of the PreTRM Test. This delay could strain financial resources.
European Market Entry: The company plans to transition its PreTRM Test to an immunoassay for the European market, but regulatory approval and successful commercialization are not guaranteed. Delays or failures in these areas could limit international growth.
Financial Performance: Net revenue for the quarter was only $17,000, a decline from the previous year, while operating expenses remain high at $9.3 million. This imbalance highlights the financial risk of sustaining operations without significant revenue growth.
Regulatory and Reimbursement Challenges: The company faces hurdles in obtaining regulatory approvals and broadening reimbursement for its PreTRM Test, both in the U.S. and Europe. These challenges could delay market adoption and revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Publication of PRIME study results: The company plans to publish the full PRIME study results in a peer-reviewed journal before the end of the year, including new data on the efficacy of the PreTRM Test.
Medicaid cost savings and pilot programs: Sera Prognostics expects Medicaid programs to realize cost savings from the PreTRM Test, with potential pilot program signings in 2-4 states in the coming months.
Commercial expansion and sales efforts: The company is focusing sales and marketing efforts in specific geographies with synergistic opportunities, hiring additional sales representatives, and expects new representatives to drive adoption within a few quarters.
European market entry: Plans to transition the PreTRM Test to an immunoassay and submit for regulatory approval in the U.K., France, and Germany by early 2026, with commercial implementation targeted for mid-2026.
Data dissemination and guideline influence: Sera aims to share health economic benefits and PRIME data at upcoming conferences, including a European conference this fall and the SMFM Annual Pregnancy Meeting in February 2026, to influence guideline updates.
Commercialization performance indicators: The company plans to start reporting key commercialization performance indicators, including sales activity metrics, payer contract wins, and revenue, as commercialization gains momentum.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about how we should be thinking about the different milestones as you continue to build out your commercial sales force? Has there been any shifts or changes since Lee joined?
A:Lee has brought decades of experience in commercialization and has emphasized the role of the test in augmenting care protocols for pregnancy. He has focused on expanding the commercial team with experienced sales leaders and upgrading team capabilities, including market access. This has allowed the company to address both commercial and public payers effectively.
Q:Can you update us on how conversations have progressed with guideline bodies and your expectations for getting into guidelines?
A:Conversations with guideline bodies have been rich and engaging, with interest from opinion leaders, clinicians, and payers. The PRIME study data has generated excitement due to its breakthrough results, such as saving 1 out of 5 babies from NICU admission. However, additional data analysis has been required, delaying progress.
Q:What is the rationale for pursuing the EU market despite the large U.S. market? Will this increase costs?
A:The company sees a global impact opportunity and has received encouragement from European opinion leaders. They plan to commercialize in Europe through partnerships, minimizing costs by sharing commercialization expenses with partners. Investments have been made to prepare the product for commercialization, with high ROI expected.
Q:How many sales reps have you hired this quarter, and how does getting coverage in high-population Medicaid states drive hiring?
A:The company has about a 10% sales force and is ready to hire more as traction increases. They focus on achieving reimbursement in specific geographies before expanding. By year-end, they aim to have 4 to 6 geographies with reimbursement, enabling targeted hiring to drive adoption among providers.
Q:Have you received any positive feedback regarding the ACOG 234 bulletin or tailored care approaches?
A:The ACOG's shift towards tailored care pathways for low-risk pregnancies aligns with the company's test, which provides risk stratification. This change supports the inclusion of innovative tools like their test. Opinion leaders are awaiting upcoming data to evaluate the test's inclusion in tailored care protocols.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of sales reps hired this quarter and the exact geographies targeted for reimbursement. Additionally, they did not share specific feedback from opinion leaders regarding the ACOG 234 bulletin, citing confidentiality.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Europe
Head
Investor Relations
Jen
Medicaid plan
Medicaid program
NICU day
Research Division
Test state
agency
building
clinician
commercialization
cost NICU
cost saving
geography
government
health benefit
health care
market awareness
momentum
month health
opinion leader
organization
pilot program
plan pilot
presence
program month
quarter
reach
reimbursement
representative
role
sale effort
sale marketing
saving member
side
state Medicaid
year experience
SERA Transcript
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals several concerns: declining revenue, increased operating expenses, and a slight rise in net loss, indicating financial struggles. The shift from R&D to commercial efforts could hinder future innovation. Additionally, challenges in payer engagement and European market entry pose risks. While management remains optimistic about partnerships and Medicaid coverage, the lack of specific metrics and timelines, coupled with potential delays, adds uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects mixed sentiments. While there are positive aspects like disciplined expense management and promising partner programs, the company faces significant commercialization challenges and financial losses. The Q&A section indicates some optimism with stakeholder engagement and strategic partnerships, yet uncertainties in payer coverage and market access persist. The financial metrics reveal modest revenue and ongoing losses, with a stable cash position but slow growth. These factors balance out, leading to a neutral stock price prediction in the short term.
Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call highlights several concerns: a decline in net revenue, high operating expenses, and challenges in regulatory and reimbursement approvals. The Q&A reveals delays in guideline inclusion and vague responses on sales force expansion. Despite plans for European market entry, the financial strain and uncertainties overshadow potential growth. The stock price is likely to experience a negative reaction in the short term due to these factors.
SERA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
